more medical resources during the 12-month follow-up period, including increases in days hospitalized (+138.2% Medicare, +173.5% private), days requiring home health care (+85.4% Medicare, +230.0% private), emergency department visits (+40.6% Medicare, +109.0% private), and outpatient/physician office visits (+35.1% Medicare, +42.5% private). This resulted in costs among DFU patients of approximately twice that of matched non-DFU diabetic patients, with annual incremental per-patient healthcare costs of $11,296 for Medicare and $15,329 for privately-insured patients. These findings suggest an annual payer burden associated with DFUs of up-to $15 billion.
A poster presentation, titled "Medical, Drug and Work-loss Costs of Venous Leg Ulcers," unveiled findings from the first study to analyze the US resource and economic burden imposed by VLUs, which are the most frequently occurring type of chronic leg wound, estimated to affect approximately 2.5 million patients in the US per year.,
Results showed that compared to non-VLU matched patients, VLU patients were found to be nearly twice as costly as the general population for private payers and 50% more costly for Medicare. VLU patients utilized more medical resources, including more days hospitalized (+80.6% Medicare, +83.5% private), days requiring home health care (+74.4% Medicare, +202.8% private), emergency department visits (+36.5% Medicare, +46.9% private), and outpatient/physician office visits (+27.3% Medicare, +39.7% private). These findings suggest an annual payer burden of up to $18 billion.
"These startling results highlight the urgent crisis posed on our health care system by DFUs and VLUs, and should serve as a call to action for improving both the prevention and aggressive treatment of these wounds," said Geoff MacKay , president and CEO of Organogenesis Inc. "With approaches currently available, including living cPage: 1 2 3 4 Related biology technology :1
. Organogenesis Announces Annual College Scholarship Award Winner2
. Cempra Presents Post-Phase 2 Analysis of Solithromycins Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP)3
. Trigemina Presents at American Pain Society 32nd Annual Scientific Meeting4
. Patheon Exhibits and Presents at the 2013 IQPC Global Formulation and Drug Delivery Summit5
. Upsher-Smith Presents Favorable Phase I Data For USL261, A Novel Formulation Of Intranasal Midazolam, At 65th Annual Meeting Of The American Academy Of Neurology6
. Assemblyman Levine Presents Resolution Recognizing Rare Disease Day at Capitol7
. Drogueria Americana, a Honduran Affiliate of GeneCell International, Presents to a Panel of More Than 100 Leading Dentist on Dental Pulp Stem Cells8
. Cellular Biomedicine Group President Presents Keynote Address at New York Stem Cell Summit9
. Bluestar Silicones Presents Soft Silicone Advantages At Medical Design And Manufacturing (MD&M) West Show10
. Oracle’s Value Chain Summit San Francisco: Track Sponsor NexInfo presents more industry specific solutions11
. Fertility Associates of Memphis, World-Renowned Expert in Infertility, Presents Findings to European Conference